Analyst consensus rating
Beam Therapeutics Analyst Rating: Strong Buy
Direct answer
Beam Therapeutics's consensus rating is Strong Buy.
13 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $49.38.
Forecast evidence checked November 4, 2026.
Get free Beam Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $26.33
- Average price target
- $49.38
- High price target
- $80.00
- Low price target
- $26.00
- Low target gap
- -1.3%
- Target upside
- +87.6%
- High target gap
- +203.8%
- Target range width
- 205.1%
- Consensus rating
- Strong Buy
- Analysts
- 13
- Evidence date
- November 4, 2026
- Valid through
- November 11, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Beam Therapeutics?
Beam Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $49.38.
How far are Beam Therapeutics's low and high targets from the recorded price?
The low target implies -1.3%, while the high target implies +203.8%.
How many analysts are included in Beam Therapeutics's consensus?
The verified consensus includes 13 analysts.
How is Beam Therapeutics's target upside or downside calculated?
The average target of $49.38 is divided by the recorded price of $26.33, then one is subtracted to produce +87.6%. This does not guarantee a future return.
When was Beam Therapeutics's analyst forecast verified?
The data was verified on 2026-11-04. The dataset is valid through 2026-11-11.